Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Alembic Pharmaceuticals Ltd - 533573 - Board Meeting Intimation for Unaudited Financial Results For The Quarter Ended 30Th June, 2021

 ALEMBIC PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/07/2021 ,inter alia, to consider and approve With reference to the captioned matter, the exchange is hereby informed that a Meeting of Board of Directors of the Company will be held on Monday, 26th July, 2021, inter-alia to consider and approve Unaudited Financial Results of the Company for the quarter ended 30th June, 2021. Pursuant to the Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons and their Immediate Relatives, the trading window for dealing in securities of the Company which was closed from 1st July, 2021, will re-open 48 hours after the declaration of the financial results. We request you to kindly take the same on record.
15-07-2021
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the Company has issued Duplicate Share Certificate(s) to the registered shareholder(s) and / or their legal heir(s) on 13th July, 2021 as per the attached documents. We enclose herewith an intimation received from Link Intime India Private Limited, Registrar and Share Transfer Agent giving the proof of the date of receipt of aforesaid information by the Company. We request you to kindly take the same on record.
13-07-2021

Alembic Pharmaceuticals Q1 PAT may dip 28.7% YoY to Rs 215 cr: KRChoksey

 Net Sales are expected to decrease by 5.6 percent Y-o-Y (down 1.1 percent Q-o-Q) to Rs 1,266 crore, according to KRChoksey.
13-07-2021

Alembic Pharma gets USFDA nod for cancer treatment drug

 The approved product is therapeutically equivalent to the reference listed drug product Tarceva tablets of OSI Pharmaceuticals, LLC.
09-07-2021
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Final Approval for Erlotinib Tablets, 25 mg, 100 mg, and 150 mg. Please find enclosed herewith our press release. We request you to kindly take the same on record.
09-07-2021

Alembic Pharma gets USFDA approval for anti-depressant drug

 The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Desipramine Hydrochloride tablets USP
08-07-2021
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Final Approval for Desipramine Hydrochloride Tablets USP, 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, and 150 mg. Please find enclosed herewith our press release. We request you to kindly take the same on record.
08-07-2021
Bigul

Alembic Pharmaceuticals Ltd - 533573 - Shareholding for the Period Ended June 30, 2021

 Alembic Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2021. For more details, kindly Click here
07-07-2021
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Statement Of Investor Complaints For The Quarter Ended June 2021

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- Charandeep Singh SalujaDesignation :- Company Secretary and Compliance Officer
07-07-2021
Bigul

Alembic Pharmaceuticals Ltd - 533573 - Statement Of Investor Complaints For The Quarter Ended June 2021

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- Charandeep Singh SalujaDesignation :- Company Secretary and Compliance Officer
07-07-2021
Next Page
Close

Let's Open Free Demat Account